

Int'l App. No.: PCT/GB00/01520

Int'l Filing Date: 19 April 2000

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

An abstract has been added.

In the Claims:

Claims 11-13 have been cancelled.

1. (Amended) A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) [characterized in that it provides:] comprising:

comprising:

- (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm^{-1} ; and/or
- (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm^{-1} ; and/or
- (iii) a solid-state ^{13}C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or
- (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms.

3. (Amended) A Polymorph according to claim 1 [or claim 2], which provides [provides] a Raman spectrum substantially in accordance with Figure II.

4. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 3], which provides a solid-state ^{13}C nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.

5. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 3], which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.

6. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 5], in isolated form.

7. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 6], in pure form.

8. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 7], in crystalline form.

Int'l App. No.: PCT/GB00/01520
Int'l Filing Date: 19 April 2000

14. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph according to claim 1 to a human or non-human mammal in need thereof.

14. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph according to claim 1 to a human or non-human mammal in need thereof.